• IceCure Medical announced IRB clearance at West Cancer Center to start the ChoICE post-marketing study of ProSense in low-risk breast cancer.
• Patient enrollment is expected in the coming weeks, expanding real-world evidence for a device already cleared for use in women aged 70 and older.
• Earlier ICE3 trial results have already been presented, supporting FDA marketing authorization and showing low recurrence with favorable cosmetic satisfaction.
• The new study aims to reinforce adoption by validating outcomes in routine practice, supporting commercial uptake in an older patient segment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IceCure Medical Ltd. published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.